Billionaires Stanley Druckenmiller, Chase Coleman, and Stephen Mandel Jr. Are Piling Into This Growth Stock That's Beating the S&P 500

When looking for investment inspiration, it's a great idea to consider what some of the world's most successful investors are doing. Each one of their moves may not be right for your particular investment strategy, but you may find certain ones that offer just what you're looking for. If  you're looking for a low-risk growth stock that also happens to be outperforming the S&P 500 (SNPINDEX: ^GSPC) so far this year, it's time to consider a recent move made by three billionaires.Stanley Druckenmiller of the Duquesne Family Office, Chase Coleman of Tiger Global Management, and Stephen Mandel Jr. of Lone Pine Capital each bought shares of a stock that operates in an industry known for steady performance, regardless of the market environment. It's in the pharmaceuticals sector but sells a product that's generating outsized revenue growth. This stock could be particularly interesting during times of economic uncertainty -- like today -- because of this solid combination of safety and growth.Image source: Getty Images.Continue reading

Mar 28, 2025 - 08:50
 0
Billionaires Stanley Druckenmiller, Chase Coleman, and Stephen Mandel Jr. Are Piling Into This Growth Stock That's Beating the S&P 500

When looking for investment inspiration, it's a great idea to consider what some of the world's most successful investors are doing. Each one of their moves may not be right for your particular investment strategy, but you may find certain ones that offer just what you're looking for. If  you're looking for a low-risk growth stock that also happens to be outperforming the S&P 500 (SNPINDEX: ^GSPC) so far this year, it's time to consider a recent move made by three billionaires.

Stanley Druckenmiller of the Duquesne Family Office, Chase Coleman of Tiger Global Management, and Stephen Mandel Jr. of Lone Pine Capital each bought shares of a stock that operates in an industry known for steady performance, regardless of the market environment. It's in the pharmaceuticals sector but sells a product that's generating outsized revenue growth. This stock could be particularly interesting during times of economic uncertainty -- like today -- because of this solid combination of safety and growth.

Image source: Getty Images.

Continue reading